RSS

diffuse large B-cell lymphoma (DLBCL)

Clinical-stage, biopharmaceutical start-up company, Autolus, steps into the chimeric antigen receptor (CAR)-T cell therapy fray with three new studies looking at the treatment of various cancers. more

News

Scientists from the University of Southampton are commencing a trial of an experimental drug, combined with immunochemotherapy, to treat certain patients with diffuse large B-cell lymphoma (DLBCL). more

News

The FDA has granted breakthrough therapy designation to Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy, CTL019 more

News